Japanese Encephalitis Vaccine Indications and dosage Intramuscular Active immunisation against encephalitis due to japanese encephalitis virus Adult: As adsorbed, inactivated virus vaccine: primary immunisation: 0.5 ml at 0 and 28 days. Alternatively, an accelerated schedule consisting of 0.5 ml at 0 and 7 days may be given when there is insufficient time for the standard course. primary course should be complete at least 1 week before potential exposure. booster dose: given 12-24 months ( 12 months for those at continued risk ) after the primary course. Child: primary immunisation:2 months to <3 years 0.25 ml at 0 and 28 days; > 3-17 years same as adult dose. booster dose: Given 12- 24 months ( 12 months for those at continued risk ) after the primary course. Active immunisation. Subcutaneous Active immunisation againts encephalitis due to japanese encephalitis virus Adult: As live, attenuated virus vaccine: primary immunisation: 0.5 ml as single dose. booster dose: may be given 5 years after the primary dose, in patients at continued risk. Child: 9 months to 17 years primary immunisation: 0.5 ml as single dose. booster dose: given 12- 24 months after the primary dose, in patients at continued risk. Contraindications Hypersensitivity. live, attenuated virus vaccine: congenital or acquired immunodeficiency ( e.g. HIV infection ). pregnancy and lactation ( live, attenuated virus vaccine ). Special Precaution Patients with bleeding disorders ( e.g thrombocytopenia, haemophilia ), altered immunocompetence, personal or family history of febrile convulsions. postpone vaccination in case of acute severe febrile or acute illness. children. pregnancy and lactation ( adsorbed, inactivated virus vaccine ). Japanese Encephalitis Japanese Encephalitis (JE) is a vector-borne viral zoonosis that also affects humans. JE virus is a member of the vector-borne flaviviruses, with similarities to several other flaviviruses such as dengue fever and west nile virus. JE occurs in practically all asian countries. The major genotypes of the virus different geographical distributions, but all belong to the same serotype and are similar in terms of host preference and virulence. following an infectious mosquito bite, the virus replicates in local and regional lymph nodes which may be followed by viral invasion of the central nervous system. infection is characterized by sudden onset of fever, chills, myalgias, and mental confusion. in children gastrointestinal pain and vomiting may be the dominant initial symptoms and convulsions are very common. nearly 3 billion people are believed to be at risk for JE virus infection and approximately 20,000 clinical cases with 6,000 deaths are reported annually. the case fatality rate ranges from 5-30% but approximately 30-50 % of the surviving patients have permanent neuropsychiatric sequelae and complete recovery occurs in only one-third of patients. JE Vaccine Vaccination of the human is the most effective means of preventing JE. there are three types of inactivated vaccines and one type of live attenuated vaccine currently used in the world: Japanese Encephalitis is a rare but serious infection you can get from mosquito bites in some parts of the world. if you're travelling to an area where there's a risk of catching it, you can get a vaccine to help prevent it.
No comments:
Post a Comment